Supercharged immune cells take on pancreatic cancer in new trial

NCT ID NCT07480928

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new type of immunotherapy for people with advanced pancreatic cancer that has spread or cannot be removed. The treatment uses specially engineered natural killer (NK) cells that target two cancer-related proteins at once. Up to 42 participants will receive these cells along with chemotherapy to prepare the body, and researchers will monitor safety and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dual-targeting CAR-NK cells (engineered immune cells) targeting MSLN and MUC1 or CLDN18.2 and MUC1, plus lymphodepleting chemotherapy
What this could lead to
If successful, this could point toward a new treatment option for advanced pancreatic cancer that is hard to treat with current therapies.
What could go wrong
This is an early phase 1/2 trial with only 42 participants, so results may not apply broadly. CAR-NK therapy can cause serious side effects like cytokine release syndrome or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, 518036, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.